Neal Andrew J, Campbell Bruce C V, Chandratheva Arvind, Hand Peter J, Davis Stephen M
Department of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Grattan Street, Parkville, VIC 3052, Australia.
Department of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Grattan Street, Parkville, VIC 3052, Australia.
J Clin Neurosci. 2014 Nov;21(11):2013-5. doi: 10.1016/j.jocn.2014.03.029. Epub 2014 Jun 28.
The risk of thrombolysis in patients taking novel anticoagulants remains unclear. We describe a patient with a large acute ischaemic stroke, who had a low calibrated anti-factor Xa level, who safely received thrombolysis 15-17 hours after standard dose rivaroxaban without subsequent intracerebral haemorrhage.
服用新型抗凝剂的患者进行溶栓治疗的风险仍不明确。我们描述了一名患有大面积急性缺血性中风的患者，其校准后的抗Xa因子水平较低，在服用标准剂量利伐沙班15 - 17小时后安全接受了溶栓治疗，且随后未发生颅内出血。
